Evidence is accumulating that active surveillance is an appropriate way to manage low-risk prostate cancer in selected men, with curative treatment delayed until it is warranted by indicators of disease progression. This evidence includes data showing that active surveillance does not cause a significant increase in prostate-cancer mortality compared with immediate treatment. In fact, an independent panel of the National Institutes of Health in December 2011 concluded that active surveillance is a viable option that should be offered to patients with low-risk prostate cancer.
Renal & Urology News wants to know how urologists view active surveillance today compared with five years ago. Please take a few moments to answer our latest poll question: